Reports Q4 revenue $35M, consensus $42.5M. “2023 was a breakout year for Ginkgo,” said Jason Kelly, co-founder and CEO of Ginkgo. “We’re working to build a durable platform that fundamentally transforms R&D in biotech. I’m particularly pleased with our growth in biopharma, which represents our largest untapped market – we added several new programs across modalities with large enterprises including Boehringer Ingelheim, Merck, Novo Nordisk, and Pfizer and are seeing strong momentum in pharma going into 2024. I am also thrilled to see a real ecosystem building around Ginkgo – we’re honored by the trust placed in us by the terrific founders of Patch Biosciences, Reverie Labs, and Proof Diagnostics to bring their technologies to customers and by the over 25 inaugural partners in our newly announced Technology Network. We are committed to bringing the best technologies together to support our customers, and we’ve never been better positioned to deliver.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DNA:
- Ginkgo Bioworks acquires Proof Diagnostics, no terms disclosed
- Ginkgo Bioworks acquires Patch Biosciences, no terms disclosed
- Ginkgo Bioworks acquires key assets of Reverie Labs, no terms
- Ginkgo Bioworks Acquires Patch Biosciences, Expanding Suite of Genetic Medicine Capabilities Available to Customers
- Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers